PDS Biotechnology Financial Results
PDS Biotechnology reported third quarter 2026 financial results, highlighting a strategic shift to PDS0301 as its lead development program. The company also noted the initial closing of a $22.3 million PIPE financing led by Nant Capital and the appointment of several new board members, including Dr. Patrick Soon-Shiong.
“During our third quarter, we continued to execute our strategic prioritization of PDS0301, our investigational tumor-targeted IL-12 immunocytokine, as our lead development program. We believe the ongoing clinical trials of PDS0301 at the NCI, along with those of our cancer vaccine platform, support our view that targeted T cell immunotherapy has the potential to change how solid tumors are treated.”
Frank Bedu-Addo, PhD, President and Chief Executive Officer